Trial No. Principal Investigator Trial Name
TRIO-US Lilly 13Y-MC-JPBK Babu A Randomized Phase 3 Study of Abemaciclib plus Best Supportive Care versus Erlotinib plus Best Supportive Care in Patients with Stage IV NSCLC with a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
TRIO-US BMS CA209-370 Babu A master protocol of Phase 1/2 Studies of Nivolumab in advanced NSCLC using Nivolumab as maintenance after induction chemotherapy or as first-line treatment alone or in combination with standard of care therapies
TRIO-US BMS CA209-384 Sadiq A dose frequency optimization, Phase IIIB/IV Trial of Nivolumab 240mg every 2 weeks vs Nivolumab 480mg every 4 weeks in subjects with advanced or metastatic Non-Small Cell Lung Cancer who received 4 months of Nivolumab at 3mg/kg or 240 mg every 2 weeks
Genentech GO29438 Sadiq A phase III, open-label, randomized study of Atezolizumab (MPDL3280A, anti-PD-L1 antibody) in combination with carboplatin or cisplatin+pemetrexed compared with carboplatin or cisplatin+pemetrexed in patients who are chemotherapy-naïve and have stage IV non-squamous non-small cell lung cancer